Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA
  • Print
  • Share
  • E-mail
-

FDA-TRACK Home Page or Center for Biologics Evaluation and Research Index

Percentage of advisory committee members and temporary voting members granted conflict of interest waivers during the quarter

Dictionary: When CBER determines that an advisory committee member and voting member has a financial conflict of interest, the agency may grant a waiver that allows the member to participate in an advisory committee meeting if certain criteria and policies are met. In general, CBER may grant a waiver if the member's expertise is considered essential to the committee’s discussions and recommendations. CBER must also take into consideration a cap on the number of waivers that can be granted each year. CBER searches for experts who have the necessary expertise without conflicts of interest; yet, in some cases, many of the top authorities in specialized scientific fields may have a conflict of interest. When CBER grants a waiver, the financial interests associated with the waiver are posted on CBER’s website along with the reasons for granting the waiver.

Information is current as of June 30, 2021. Data collection is delayed due to COVID-19 priorities.

Fiscal Year - 2021

Skip graphic and jump to text data

TimeTargetPercent
Oct - Dec 2020N/A2.5
Jan - Mar 2021N/ATBD
Apr - Jun 2021N/A2.6
Jul - Sept 2021N/ATBD

FY 2021 YTD: 2.5%

Number of CBER advisory committee members and temporary voting members granted a conflict of interest waiver this quarter.

Fiscal Year - 2021
Skip graphic and jump to text data.

TimeTargetNumber
Oct - Dec 2020N/A2
Jan - Mar 2021N/ATBD
Apr - Jun 2021N/A1
Jul - Sept 2021N/ATBD

FY 2021 YTD: 3

Number of CBER advisory committee members and temporary voting members attending meetings this quarter.

Fiscal Year - 2021
Skip graphic and jump to text data.

TimeTargetNumber
Oct - Dec 2020N/A80
Jan - Mar 2021N/ATBD
Apr - Jun 2021N/A39
Jul - Sept 2021N/ATBD

FY 2021 YTD: 119

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.
-
-